GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED UNAUDTIED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2026

(Rs. in Lakhs)

	Particulars	3 months ended 30.09.2026	Preceding 3 months ended 30.06.2026	Corresponding 3 months ended 30.09.2025	6 months ended 30.09.2026	6 months ended 30.09.2025	Year ended 31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	118357	93844	97994	212201	178511	382167
2	Other income (Refer Note 2)	7278	4376	3357	11654	7729	14536
3	**Total Income (1+2)**	**125635**	**98220**	**101351**	**223855**	**186240**	**396703**
	Expenses						
	(a) Cost of materials consumed	12892	7295	11513	20187	24319	43615
	(b) Purchases of stock-in-trade	27904	37862	23272	65766	46478	91045
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	3652	(12363)	768	(8711)	(6473)	446
	(d) Employee benefits expense	17019	15904	13805	32923	29062	60725
	(e) Finance costs	49	97	51	146	93	273
	(f) Depreciation and amortisation expense	1502	1584	1743	3086	3295	6644
	(g) Other expenses	16683	15596	15063	32279	26432	55416
4	**Total expenses**	**79701**	**65975**	**66215**	**145676**	**123206**	**258164**
5	**Profit before exceptional items and tax (3-4)**	**45934**	**32245**	**35136**	**78179**	**63034**	**138539**
6	Exceptional items [credit] (Refer Note 3)	-	-	264	-	264	2062
7	**Profit before tax (5+6)**	**45934**	**32245**	**35400**	**78179**	**63298**	**140601**
8	Tax expense						
	(a) Current tax	12177	8197	9607	20374	17002	36057
	(b) Deferred tax	169	330	44	499	46	946
9	**Profit for the period/year (7-8)**	**33588**	**23718**	**25749**	**57306**	**46250**	**103598**

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED UNAUDTIED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2026

(Rs. in Lakhs)

	Particulars	3 months ended 30.09.2026	Preceding 3 months ended 30.06.2026	Corresponding 3 months ended 30.09.2025	6 months ended 30.09.2026	6 months ended 30.09.2025	Year ended 31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
10	Other comprehensive income/ (loss)						
	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	(998)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	244
11	**Total comprehensive income for the period (9+10)**	**33588**	**23718**	**25749**	**57306**	**46250**	**102844**
12	**Total comprehensive income for the period attributable to owners of the Group**	**33588**	**23718**	**25749**	**57306**	**46250**	**102844**
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941	16941	16941
	Other equity						209801
	Earnings per share (EPS) (of Rs. 10 each)						
	Basic and diluted EPS before Exceptional items (Rs.)	19.83	14.00	15.07	33.83	27.17	60.11
	Basic and diluted EPS after Exceptional items (Rs.)	19.83	14.00	15.20	33.83	27.30	61.15
		Not Annualised					

	Statement of Assets and Liabilities	Consolidated (Rs. in Lakhs)	
	Particulars	**As at 30.09.2026**	**As at 31.03.2026**
		Unaudited	**Audited**
A	**ASSETS**		
1	Non-Current Assets		
	(a) Property, Plant and Equipment	24902	24176
	(b) Right of use Assets	3695	3175
	(c) Capital work-in-progress	3481	3293
	(d) Investment Property	60	66
	(e) Intangible assets	600	656
	(f) Financial Assets		
	i. Investments	87	87
	ii.Other financial assets	1391	1344
	(g) Current tax assets (net)	17853	17853
	(h) Deferred tax assets (net)	12886	13385
	(i) Other non-current assets	8889	7734
	Total non-current assets	**73844**	**71769**
2	Current assets		
	(a) Inventories	55439	45755
	(b) Financial assets		
	(i) Current Investments	152401	139096
	(ii) Trade receivables	33941	27311
	(iii) Cash and cash equivalents	65075	110205
	(iv) Bank balances other than (iii) above	4377	28897
	(v) Other financial assets	6772	3916
	(c) Other current assets	5009	5438
	Total current assets	**323014**	**360618**
	Total Assets	**396858**	**432387**

	Statement of Assets and Liabilities	Consolidated (Rs. in Lakhs)	
	Particulars	**As at 30.09.2026**	**As at 31.03.2026**
		Unaudited	**Audited**
B	**EQUITY AND LIABILITIES**		
	Equity		
	(a) Equity Share Capital	16941	16941
	(b) Other Equity	171164	209801
	Total equity	**188105**	**226742**
	Liabilities		
1	Non-current liabilities		
	(a) Financial Liabilities		
	i. Lease liabilities	1668	1727
	(b) Provisions	26507	26007
	Total non-current liabilities	**28175**	**27734**
2	Current liabilities		
	(a) Financial Liabilities		
	i. Lease liabilities	2257	1600
	ii.Trade payables		
	Due to Micro Enterprises and Small Enterprises	640	671
	Due to others	55229	56351
	iii.Other financial liabilities	11551	10956
	(b) Other current liabilities	7376	11818
	(c) Provisions	45658	41915
	(d) Current tax liabilities (net)	57867	54600
	Total current liabilities	**180578**	**177911**
	Total liabilities	**208753**	**205645**
	Total equity and liabilities	**396858**	**432387**

	Statement of Cash Flows	Consolidated (Rs. in Lakhs)	
	Particulars	Period ended 30.09.2026	Period ended 30.09.2025
		Unaudited	Unaudited
A.	**CASH FLOWS FROM OPERATING ACTIVITIES**		
	Profit before exceptional items and tax	**78179**	**63034**
	Adjustments for :		
	Loss/(Gain) on disposal of property, plant and equipment (net)	15	(13)
	Interest income	(2716)	(2895)
	Gain on Mutual Funds	(4702)	(3941)
	Finance costs	146	93
	Depreciation and amortisation expense	3086	3295
	Allowance/(writeback) for doubtful debts and advances	(6)	148
	Interest on IT refund	(4209)	-
	Excess Provision written back	-	(220)
	Operating Profit before working capital changes	**69793**	**59501**
	Change in operating assets and liabilities		
	(Increase) in inventories	(9683)	(5419)
	(Increase) in trade receivables	(6624)	(4193)
	(Increase)/Decrease in other assets	(4824)	5488
	(Decrease) in trade payables	(722)	(22109)
	Increase in provisions	4243	1893
	(Decrease) in other liabilities	(3932)	(6167)
	Cash generated from operations	**48251**	**28994**
	Income taxes paid (net of refunds)	(17107)	(10620)
	Net cash generated from operating activities (A)	**31144**	**18374**
B.	**CASH FLOWS FROM INVESTING ACTIVITIES**		
	Payments to acquire property, plant and equipment and other intangible assets	(2670)	(1704)
	Proceeds from sale of property, plant and equipment	35	79
	Sale / redemption of mutual funds	48696	62755
	Investment in mutual funds	(57300)	(81285)
	Margin money deposits matured/(placed)	30	(12)
	Investment in bank deposits (having original maturity more than 3 months but less than 12 months)	(237785)	(201936)
	Redemption / maturity of bank deposits (having original maturity more than 3 months but less than 12 months)	262706	247868
	Advance towards sale of Property	-	1818
	Interest received	4112	6220
	Interest on IT refund	4209	-
	Cash inflow from investing activities before exceptional items	**22033**	**33803**
	Exceptional items:		
	Proceeds from sale of property	-	264
	Income taxes on Exceptional items	-	(38)
	Net cash inflow from investing activities (B)	**22033**	**34029**
C.	**CASH FLOWS FROM FINANCING ACTIVITIES**		
	Interest other than on lease liabilities	7	29
	Interest paid on lease liabilities	(154)	(123)
	Principal payment of lease liabilities	(1167)	(798)
	Dividend paid to shareholders	(96993)	(71403)
	Net cash outflow from financing activities (C)	**(98307)**	**(72295)**
	Net decrease in cash and cash equivalents (A+B+C)	**(45130)**	**(19892)**
	Cash and cash equivalents at the beginning of the year	110205	53885
	Cash and cash equivalents at the end of the period	65075	33993
	Net decrease in cash and cash equivalents	**(45130)**	**(19892)**

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 03rd November 2026. The Statutory auditors have carried out a limited review of the consolidated financial results for the quarter and six months ended 30th September 2026.
2. Other Income for the quarter and six months ended 30th September 2026 includes interest on Income Tax refund of Rs. 4209 lakhs.
3. Exceptional items credit for the year ended 31st March 2026 includes Rs. 264 lakhs on account of profit on sale of surplus residential properties and Rs 1798 lakhs on account of sale of non operational land site.
4. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.

By Order of the Board

Bhushan Akshikar
Managing Director
DIN: 09112346

03rd November, 2026